Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Introduction The safety of biologic therapies has been well documented in inflammatory bowel disease (IBD) patients without significant comorbidity; however, data pertaining to the safety of biologic therapies in high-risk patient subgroups such as solid organ transplant (SOT) recipients, remain comparatively limited given their exclusion from clinical trials [1].
Supporting Information Filename Description imj16631-sup-0001-Figures.pptxPowerPoint 2007 presentation , 318.9 KB Figure S1. Kaplan–Meier analysis of (A) patient survival and (B) graft survival of patients according to their regional code. Figure S2. Kaplan–Meier analysis of (A) patient survival and (B) graft survival of patients according to their Index of Relative Socio-Economic Disadvantage score. Figure S3.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
